Paul Cernohous

Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine

Dale J. Kempf, Martin King, Barry Bernstein et al. · The Journal of Infectious Diseases · 2004 · 221 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacotherapy +17

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial

Ruth Pettengell, Bertrand Coiffier, Geetha Narayanan et al. · The Lancet Oncology · 2012 · 120 citations

Medicine, Oncology, Pharmacology +14

Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma

Raoul Herbrecht, Paul Cernohous, Andreas Engert et al. · Annals of Oncology · 2013 · 57 citations · Full text

Medicine, Oncology, Pharmacology +6

Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor-Based Antiretroviral Therapy for Treatment-Naive HCV-HIV-Coinfected Patients: Lopinavir-Ritonavir versus Nelfinavir

Kenneth E. Sherman, Norah J. Shire, Paul Cernohous et al. · Clinical Infectious Diseases · 2005 · 32 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Baseline HIV‐1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy–Naive Patients

Martin King, Barry Bernstein, Sharon Walmsley et al. · The Journal of Infectious Diseases · 2004 · 32 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17